

CDISC 2019 Europe Interchange Amsterdam, Netherlands | 6-10 May





Real-world data From observational research to clinical trials

Presented by Sonia Araujo Director of Product Management, IQVIA UK

09.05.2019


COISC 2019 Europe Interchange Amsterdam, Netherlands | 6-10 May 2019





Observational Research





Regulatory Input



FDA's Real World Evidence Program

"...FDA uses RWD and RWE to monitor post market safety and adverse events and to make regulatory decisions..."

from FDA's RWE webpage

see also: Framework outline for RWE Program implementation, Dec 2018





Regulatory Input




HMA-EMA Joint Big Data Taskforce

"...much may be gained from the rational use of Big Data in a regulatory context for approval and monitoring of efficacy / effectiveness and safety of medicines, medical devices and combinations thereof..."

from Summary Report, Feb 2019





What is OMOP?

Common Data Model that standardizes longitudinal patient data for the purpose of observational research

- Includes its own vocabulary
 - Links to SNOMED, ICD and RxNorm
- In the public domain / open-source
- Managed by OHDSI
 - Research collaborative
 - Multiple stakeholders & geographies
 - Access to 700M patients







From Multiple Study Coding...

cdisc


"What's the adherence to my drug in the data assets of interest?"





- Reliant on partner capabilities
- Not scalable
- Not transparent
- Expensive
- Slow
- Prohibitive to non-expert routine use

... To Data Standardization & Systematic Research




I I I I I I I I I I I I I I I I I I I	Southe	I ast Asia	I China	
Europe	UK	II Japan	India	
II So Africa	Switzerland	I I Italy	Israel	
			dardized data	

OHDSI Tools


OMOP CDM




2019 Europe Interchange | Amsterdam, Netherlands | 6-10 May 2019



Network Studies / Networks of Networks



Example of Remote Study Network: FDA BEST





Other Use Cases

- Drug safety
- Drug efficacy
- Pharmacoepi or epidemiology
- Population characterization
- Patient-level prediction
- Health economics research
- Clinical trial feasibility





CDISC Standards

• CDASH

 standard way to collect data at source across studies and sponsors

• SDTM

 data submission standard for the FDA and the PMDA

$$\mathsf{OMOP} \leftrightarrow \mathsf{CDASH} \leftrightarrow \mathsf{SDTM} = \bigotimes_{\mathcal{Q}} \mathscr{Q}$$



CDASH

Model for Data Collection

SDTMIG-MD

Implementation Guide

for Medical Devices

QRS

Questionnaires,

Ratings and Scales

SDTMIG

Implementation Guide for Tabulation

SDTM

Model for Tabulations of

Study Data

TA

Therapeutic Area

SDTMIG-AP

Implementation Guide

for Associated Persons


SDTMIG-PG*

Pharmacogenomics

Pharmacogenetics

CT

Controlled Terminology





Clinical trial data




Clean data	"Dirty" data
Reflect an experiment	Collected in real-world settings
Small (megabytes)	Gigantic (terabytes)
Owned/controlled by sponsor	Owned / controlled by primary data owner
Collected for the purpose of running a clinical trial	Secondary use





Opportunities for Collaboration

- ascertain trial feasibility
- recruit trial participants, investigators and sites
- supply real data from clinical trial subjects, or "like patients"
- identify potential extra indications for marketed drugs



- combine multiple clinical trials' data into a synthetic trial
- share data for extra analysis on outcomes
- use clinical trial data as another real-world data source



OHDSI Clinical Trials WorkGroup



Use cases	Objectives
Convert (multiple) clinical trials' data to OMOP (eg, SDTM-OMOP)	Enable aggregate / population-level analytics, create synthetic trial
Convert real-world data for use in clinical trials (eg, OMOP-CDASH)	Augment type and amount of data in an RCT ("pragmatic / enriched" studies)
Run retrospective observational studies	Identify / analyse insights from clinical data (eg, whether RCT results are generalizable, potential extra indications)
Run retrospective observational studies	Help future clinical trial feasibility assessment / design



SDTM to OMOP Example



	Derive per	1~	12	surement			nent concept sitting systolic to e (LOINC)	surement vali	
IT.STUDYID 💌			T.VS.VSDTC		S TIT.VS		VS.VSSTRESN 💌 I	T.VS.VSSTRESU	TIT.VS.VSTEST
CDISC01	CDISC01.100008	SCREEN	4/15/03	SITTING		122	122 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.100008	BASELINE	4/29/03	SITTING		146	146 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.100008	WEEK 2	5/13/03	SITTING		142	142 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.100008	WEEK 24	10/13/03	SITTING		140	140 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.100014	SCREEN	10/6/03	SITTING		110	110 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.100014	BASELINE	10/15/03	SITTING		130	130 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.100014	WEEK 2	10/31/03	SITTING		118	118 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.100014	WEEK 24	3/30/04	SITTING		170	170 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.200001	SCREEN	9/9/03	SITTING		136	136 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.200001	BASELINE	9/30/03	SITTING		140	140 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.200001	WEEK 2	10/14/03	SITTING	Y	152	152 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.200001	WEEK 24	2/2/04	SITTING		160	160 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.200002	SCREEN	9/18/03	SITTING		142	142 n	nmHg	Systolic Blood Pressure
CDISC01	CDISC01.200002	BASELINE						:	Systolic Blood Pressure
CDISC01	CDISC01.200002	WEEK 2	V	ital Si	ians -	> Meau	Jrement	5	Systolic Blood Pressure
CDISC01	CDISC01.200002	WEEK 24	v	1015	IGH3 -		Jenen	5	Systolic Blood Pressure



SDTM to OMOP Example



		ID 🔻	CODE 🔻	NAME V
VISIT_OCCURRENCE		262	ERIP	Emergency Room and Inpatient Visit
The VISIT_OCCURRENCE table contains the sp- services from one or more providers at a Care 1 system. Visits are classified into 4 settings: out room, and long-term care. Persons may transiti spisode of care (for example, treatment of a di		9201	IP	Inpatient Visit
		9202	OP	Outpatient Visit
Field	Required	9203	ER	Emergency Room Visit
visit_occurrence_id	Yes	32036	OMOP generated	Laboratory Visit
person_id	Yes	32037	OMOP generated	Intensive Care
visit_concept_id		581458	OMOP generated	Pharmacy visit
	Yes	581476	OMOP generated	Home Visit
visit_start_date	No	581477	OMOP	Office Visit
visit_start_datetime	Yes		generated	
visit_end_date	No	581478	OMOP generated	Ambulance Visit
visit_end_datetime	Yes	581479	OMOP generated	Rehabilitation Visit
visit_type_concept_id	Yes	42898160	ITCP	Long Term Care Visit

OMOP CDM is extendable

- Add new visit concepts, or custom Trial Visit domain
- Add fields to capture cycle and visit day combinations (eg, Visit 1 = Screening visit + 1 week)

PIONEER EU Project (prostate cancer)










Observational Research





Clinical Trials

Observational Research



2019 Europe Interchange | Amsterdam, Netherlands | 6-10 May 2019



Thank You!

Sonia Araujo sonia.araujo@iqvia.com

